Abbvie, Genmab's Lymphoma Treatment Meets Primary Endpoint in Phase 3 Trial

Dow Jones06-30

AbbVie and Genmab's drug combination for a type of lymphoma met the primary endpoint in a Phase 3 trial.

The companies said Monday the combination of epcoritamab and lenalidomide demonstrated statistically significant improvement in progression-free survival in adult patients with relapsed or refractory diffuse large B-cell lymphoma who received at least one prior line of therapy, as compared to treatment with rituximab plus gemcitabine plus oxaliplatin.

In the trial, the drug combination reduced the risk of disease progression and death by about 60%, the companies said.

Diffuse large B-cell lymphoma is an aggressive and often difficult-to-treat cancer, AbbVie said.

The companies said they would engage with global regulatory authorities to discuss next steps for the treatment, and plan to submit the data for presentation at a future medical meeting.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

June 29, 2026 16:43 ET (20:43 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647302118?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 04:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647302118","market":"other","top_or_hot":-1,"title":"Abbvie, Genmab's Lymphoma Treatment Meets Primary Endpoint in Phase 3 Trial","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  AbbVie and Genmab's drug combination for a type of lymphoma met the primary endpoint in a Phase 3 trial. \n</p>\n<p>\n  The companies said Monday the combination of epcoritamab and lenalidomide demonstrated statistically significant improvement in progression-free survival in adult patients with relapsed or refractory diffuse large B-cell lymphoma who received at least one prior line of therapy, as compared to treatment with rituximab plus gemcitabine plus oxaliplatin. \n</p>\n<p>\n  In the trial, the drug combination reduced the risk of disease progression and death by about 60%, the companies said. \n</p>\n<p>\n  Diffuse large B-cell lymphoma is an aggressive and often difficult-to-treat cancer, AbbVie said. \n</p>\n<p>\n  The companies said they would engage with global regulatory authorities to discuss next steps for the treatment, and plan to submit the data for presentation at a future medical meeting. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 16:43 ET (20:43 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abbvie, Genmab's Lymphoma Treatment Meets Primary Endpoint in Phase 3 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbvie, Genmab's Lymphoma Treatment Meets Primary Endpoint in Phase 3 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-30 04:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  AbbVie and Genmab's drug combination for a type of lymphoma met the primary endpoint in a Phase 3 trial. \n</p>\n<p>\n  The companies said Monday the combination of epcoritamab and lenalidomide demonstrated statistically significant improvement in progression-free survival in adult patients with relapsed or refractory diffuse large B-cell lymphoma who received at least one prior line of therapy, as compared to treatment with rituximab plus gemcitabine plus oxaliplatin. \n</p>\n<p>\n  In the trial, the drug combination reduced the risk of disease progression and death by about 60%, the companies said. \n</p>\n<p>\n  Diffuse large B-cell lymphoma is an aggressive and often difficult-to-treat cancer, AbbVie said. \n</p>\n<p>\n  The companies said they would engage with global regulatory authorities to discuss next steps for the treatment, and plan to submit the data for presentation at a future medical meeting. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 16:43 ET (20:43 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0211328371.USD","symbol_name":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2647302118","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647302118","pubTimestamp":1782765780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"AbbVie and Genmab's drug combination for a type of lymphoma met the primary endpoint in a Phase 3 trial.The companies said Monday the combination of epcoritamab and lenalidomide demonstrated statistically significant improvement in progression-free survival in adult patients with relapsed or refractory diffuse large B-cell lymphoma who received at least one prior line of therapy, as compared to treatment with rituximab plus gemcitabine plus oxaliplatin.In the trial, the drug combination reduced the risk of disease progression and death by about 60%, the companies said.Diffuse large B-cell lymphoma is an aggressive and often difficult-to-treat cancer, AbbVie said.The companies said they would engage with global regulatory authorities to discuss next steps for the treatment, and plan to submit the data for presentation at a future medical meeting.Write to Kelly Cloonan at kelly.cloonan@wsj.com Dow Jones NewswiresJune 29, 2026 16:43 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","SG9999015978.USD":"利安颠覆性创新基金A","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","ABBV":"艾伯维公司","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","BK4139":"生物科技","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4550":"红杉资本持仓","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","IE0000B7K699.USD":"RQI GLOBAL \"I\" (USD) INC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2357627491.SGD":"TRP GLOBAL VALUE EQUITY \"AH\" (SGDHDG) ACC","GMAB":"Genmab A/S","LU0069063385.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (USD) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC"},"translate_title":"艾伯维、Genmab淋巴瘤治疗3期试验达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMAB":0.9,"ABBV":0.9},"content_text":"AbbVie and Genmab's drug combination for a type of lymphoma met the primary endpoint in a Phase 3 trial. \n\n\n  The companies said Monday the combination of epcoritamab and lenalidomide demonstrated statistically significant improvement in progression-free survival in adult patients with relapsed or refractory diffuse large B-cell lymphoma who received at least one prior line of therapy, as compared to treatment with rituximab plus gemcitabine plus oxaliplatin. \n\n\n  In the trial, the drug combination reduced the risk of disease progression and death by about 60%, the companies said. \n\n\n  Diffuse large B-cell lymphoma is an aggressive and often difficult-to-treat cancer, AbbVie said. \n\n\n  The companies said they would engage with global regulatory authorities to discuss next steps for the treatment, and plan to submit the data for presentation at a future medical meeting. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 29, 2026 16:43 ET (20:43 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647302118","isCrawlerRequest":true}